Welcome to our dedicated page for Balchem news (Ticker: BCPC), a resource for investors and traders seeking the latest updates and insights on Balchem stock.
Balchem Corporation reports developments tied to its specialty ingredient manufacturing business for health, nutrition, agriculture, healthcare, and other industrial markets. The company operates through Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products, with recurring updates on segment sales, earnings, cash flow, debt, share repurchases, and conference participation.
Company news also includes product and market developments such as customized food and beverage ingredient systems, key nutrients for food, supplement, and pharmaceutical applications, animal nutrition products, choline chloride, specialty-packaged chemicals, and chelated minerals for micronutrient agriculture. Updates have included the Metalosate® T.E.A.M.™ plant tissue analysis platform and trade actions affecting choline chloride supply chains.
Balchem (NASDAQ: BCPC) reported strong third quarter 2024 financial results with net sales of $239.9 million, up 4.3% year-over-year. The company achieved record earnings from operations and adjusted EBITDA of $64.4 million, a 7.6% increase. Net earnings rose 16.4% to $33.8 million, with earnings per share of $1.03. The Human Nutrition and Health segment showed excellent performance with 5.4% sales growth, while Specialty Products grew 10.6%. Cash flows from operations were $51.3 million, with quarterly free cash flow of $42.2 million. The company's net debt decreased to $153.3 million with a leverage ratio of 0.6 times.
Balchem (NASDAQ: BCPC) has announced a conference call scheduled for Friday, October 25, 2024, at 11:00 AM Eastern Time to review their third quarter results. The call will be hosted by Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO.
The company will release its third quarter results prior to the market opening on the same day. The press release and accompanying financial exhibits will be available on the Balchem website before the call. Interested parties can join the conference by calling toll-free 1-877-407-8289 or 1-201-689-8341 for local dial-in.
A replay of the call will be available for three hours after its conclusion until November 8, 2024. To access the replay, dial 1-877-660-6853 (local dial-in 1-201-612-7415) and use conference ID #13749359.
Balchem (NASDAQ: BCPC), a global specialty ingredient manufacturer for health and nutrition markets, has announced its participation in the HC Wainwright & Co. 26th Annual Global Investment Conference on September 9, 2024. The company will be represented by key executives including Ted Harris (Chairman of the Board, President and CEO), Martin Bengtsson (CFO), and Allison Baurichter (Senior Director Investor Relations).
This presentation at a prominent investment conference provides an opportunity for Balchem to showcase its business strategies, financial performance, and growth prospects to potential investors and industry analysts. The event could potentially impact Balchem's stock performance and investor relations.
Balchem (NASDAQ: BCPC) reported strong Q2 2024 financial results with record earnings from operations and adjusted EBITDA. Key highlights include:
- Net sales of $234.1 million, up 1.2% YoY
- Adjusted EBITDA of $62.3 million, up 5.0% YoY
- GAAP net earnings of $32.1 million, up 6.5% YoY
- GAAP EPS of $0.98, compared to $0.93 in Q2 2023
- Record adjusted EPS of $1.09, up from $1.06 in Q2 2023
- Free cash flow of $38.4 million
The Human Nutrition & Health and Specialty Products segments showed strong performance with record earnings. Balchem also launched Optifolin+®, a new choline-enriched folate ingredient. The company's net debt decreased to $202.8 million, with a leverage ratio of 0.9x.
Balchem (NASDAQ: BCPC) will hold a conference call on Friday, July 26, 2024, at 11:00 AM Eastern Time (ET) to discuss second quarter financial results. The results will be published earlier that day before the market opens. Ted Harris, Chairman, President, and CEO, along with CFO Martin Bengtsson, will lead the call. The press release and financial exhibits will be available on the company's website. The call can be accessed toll-free at 1-877-407-8289, with a replay available until August 9, 2024.
Balchem (NASDAQ: BCPC), a global specialty ingredient manufacturer, will present at the CJS Securities 24th Annual New Ideas Summer Conference on July 10, 2024. The event is set to take place in Montvale, NJ. Ted Harris, Chairman, President, and CEO, along with CFO Martin Bengtsson and Senior Director of Investor Relations Allison Baurichter, will represent the company. This presentation highlights Balchem's commitment to engaging with investors and showcasing its market position in the health and nutrition sectors.
Balchem (NASDAQ: BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced it will present at the Wells Fargo Industrials Conference on June 12, 2024. The presentation will be made by Ted Harris, the Chairman of the Board, President, and CEO; Martin Bengtsson, the CFO; and Allison Baurichter, the Senior Director of Investor Relations. This conference attendance is expected to provide Balchem with a platform to discuss its latest strategies and developments with industry peers and investors.
Balchem (NASDAQ: BCPC) announced that they will attend the Deutsche Bank Global Consumer Conference on June 4, 2024, in Montvale, NJ. The company specializes in manufacturing specialty ingredients for health and nutrition markets.
Representing Balchem at the conference will be Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO. This event will provide an opportunity for the company to engage with investors and industry stakeholders.
Balchem (NASDAQ: BCPC) reported record net sales of $239.7 million, net earnings of $29.0 million, adjusted EBITDA of $60.9 million, and free cash flow of $26.8 million for the first quarter of 2024. The Human Nutrition & Health segment saw significant growth, with sales up 15.1% and earnings up 80.4% compared to the prior year. The Animal Nutrition & Health segment experienced a decrease in sales, while the Specialty Products segment remained stable. The company's strong financial performance and sustainability initiatives signal a positive outlook for 2024.
The New York Jets have announced a multi-year partnership with VitaCholine, a Balchem Human Nutrition and Health brand, marking VitaCholine's first sponsorship and the first sponsorship in the Nutritional Ingredient category of a major professional sports team. The agreement includes territorial rights in the United States and the United Kingdom, entitlement of the New York Jets official website, and presenting partner status for a Jets road game. VitaCholine will be featured prominently on the team's website and at MetLife Stadium, aiming to raise awareness about the essential nutrient choline and its health benefits. This collaboration highlights the growing demand for solutions supporting mental and physical performance in the post-pandemic era.